SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moonlake Immunotherapeutics operates as a clinical-stage biotechnology company. It offers tri-specific Nanobody, Sonelokimab to address significant unmet needs in inflammatory skin and joint diseases. The company was founded by Kristian Reich, Jorge Santos da Silva, and Arnout Ploos van Amstel in 2021 and is headquartered in Zug, Switzerland.

MoonLake Immunotherapeutics - Ordinary Shares - Class A

MoonLake Immunotherapeutics

MoonLake Immunotherapeutics is trending after announcing positive Phase 2 S-OLARIS trial results for sonelokimab in axial spondyloarthritis, showcasing "disease modifying" potential and "best-in-class" efficacy. The community anticipates a significant re-valuation and potential short squeeze, fueled by strong financial positioning and upcoming Investor Day presentations.

United States Commodity Funds LLC - United States Oil Fund

United States Oil Fund

USO is trending due to escalating US-Iran tensions, fueled by a significant US military buildup in the Middle East and President Trump's warnings of potential military action. This has sparked intense community debate over a looming "war premium" for crude oil, with some anticipating a major price surge while others point to global oversupply and potential Venezuelan output as counteracting forces.

First Majestic Silver Corp. engages in the production, development, exploration and acquisition of mineral properties. It owns and operates producing mines in México including the La Encantada Silver Mine, La Parrilla Silver Mine, San Martin Silver Mine, La Guitarra Silver Mine, Del Toro Silver Mine, Santa Elena Silver & Gold Mine, and San Dimas Silver & Gold Mine. The company was founded by Keith Neumeyer on September 26, 1979 and is headquartered in Vancouver, Canada.

First Majestic Silver Corporation

First Majestic Silver is trending following its robust Q4 and full-year 2025 earnings report, which highlighted record revenue and strong production fueled by elevated silver prices. The community is highly bullish, emphasizing the company's unique advantage of owning its own mint, its strong correlation to the metal's rising value, and its potential for significant upside amidst ongoing discussions of silver scarcity and market dynamics.

Super Group (SGHC) Ltd. is a global digital gaming company, which engages in the global online sports betting and gaming businesses, Betway, a premier online sports betting brand, and Spin, a multi-brand online casino offering. It operates through the following segments: Betway, Spin, and Other. The Betway segment focuses on the ingle brand online sportsbook and online casino focused business with a global footprint and strategic partnerships. The Spin segment relates to the multi-brand online casino focused business with established market leadership in high-growth markets. The company was founded in July 2020 and is headquartered in St. Peter Port, the United Kingdom.

Super Group (SGHC) Limited

Super Group (SGHC) is trending amid discussions of a potential short squeeze, fueled by recent strong financial results that include Q3 earnings beats, raised guidance, and a special dividend. The community highlights its debt-free, profitable status and global focus, particularly in Africa and Europe, positioning it as an undervalued player in the iGaming sector despite broader market volatility.

Abivax SA engages in the sale, research, distribution, and development of biopharmaceutical products. It offers commercial and development products of anti-viral compounds and human vaccines. The commercialized products include vaccines for typhoid fever, meningococcus, and leptospirosis. The products under development include vaccines for chronic hepatitis B, ebola, and dengue virus. The company was founded by Philippe Pouletty on December 4, 2003 and is headquartered in Paris, France.

Abivax - ADR

Abivax is trending following new positive preclinical and clinical data for its inflammatory bowel disease drug, obefazimod, presented at a major medical congress, which is intensifying rumors of a potential acquisition by major pharmaceutical companies. The community is actively discussing a looming bidding war, with many believing the stock is significantly undervalued despite company denials and official statements to the contrary.

Select Water Solutions, Inc. engages in the provision of water management and chemical solutions. It operates through the following business segments: Water Infrastructure, Water Services, and Chemical Technologies. The Water Infrastructure segment develops, builds, and operates permanent and semi-permanent infrastructure solutions to support full life cycle water management and waste treatment solutions. The Water Services segment consists of services businesses, including water transfer, flowback and well testing, fluids hauling, water containment and water network automation, primarily serving E&P companies. The Chemical Technologies segment includes logistics and provides a full suite of chemicals used in hydraulic fracturing, stimulation, cementing, pipelines and well completions. The company was founded on November 21, 2016 and is headquartered in Gainesville, TX.

Select Water Solutions Inc - Ordinary Shares - Class A

Select Energy Services Inc - Ordinary Shares - Class A

A recently priced public offering of Class A common shares at a 10% discount is sparking conversation around Select Water Solutions, as the community debates the near-term impact of dilution against the company's long-term growth plans for water infrastructure. Many investors are closely watching if robust fundamentals and strong projections for its sustainable water management business will quickly absorb the new shares.

The Compound Governance Token is a governance token on the Compound Finance lending protocol, COMP allows the owner to delegate voting rights to the address of their choice; the owner’s wallet, another user, an application, or a DeFi expert. Anybody can participate in Compound governance by receiving delegation, without needing to own COMP.  Anybody with 1% of COMP delegated to their address can propose a governance action; these are simple or complex sets of actions, such as adding support for a new asset, changing an asset’s collateral factor, changing a market’s interest rate model, or changing any other parameter or variable of the protocol that the current administrator can modify.

Compound

Compound (COMP CRYPTO) is trending as the community observes numerous bullish technical indicators and anticipates a potential supply shock given its near-max 10 million coin supply. Discussion is also active around upcoming V4 developments, new partnerships, and broader DeFi catalysts such as the "Clarity Act" that could attract institutional interest.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

SPY is drawing significant attention as market participants assess the implications of newly implemented 15% global tariffs, leading to polarized community sentiment ranging from predictions of a "bloodbath" amid geopolitical unrest to expectations that the market will quickly rebound, with many also anticipating Nvidia's upcoming earnings.

The Mullen Army Token originated from a dedicated community of retail investors who faced challenges in the traditional stock market. We united to create a cryptocurrency that embodies our principles and aspirations for a fair financial system.     We provide a platform for retail investors to engage in a transparent and fair financial market. Our efforts include grassroots marketing, community engagement, and educational content to empower our investors.

MullenArmy

Mullen Automotive ($MULN) is trending as the community reacts to the launch of a "Mullen Army" crypto token, with many former investors expressing disbelief and labeling it as a continuation of alleged scams following the stock's contentious history of reverse splits and significant investor losses.

Foghorn Therapeutics, Inc. operates as a development stage biopharmaceutical company. It is discovering and developing a novel class of precision medicine therapeutics targeting the chromatin regulatory system in oncology. Through its scalable Gene Traffic Control product platform, the firm is systematically interrogating and drugging the chromatin regulatory system. The company was founded by Cigall Kadoch, Gerald W. Crabtree and Douglas G. Cole in October 2015 and is headquartered in Cambridge, MA.

Foghorn Therapeutics Inc

Foghorn Therapeutics is trending after Eli Lilly selected its FHD-909 BRM selective inhibitor for clinical development, a significant validation of its chromatin biology platform. This news, coupled with multiple analyst upgrades, fuels community discussion around its undervaluation and potential for future milestones or acquisition in the targeted protein degradation sector.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Aberdeen Group plc Grows Stock Holdings in Vericel Corporation $VCEL

Aberdeen Group plc lifted its stake in Vericel Corporation (NASDAQ:VCEL - Free Report) by 159.5% in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The...

Vericel (VCEL) Projected to Post Quarterly Earnings on Thursday

Vericel (NASDAQ:VCEL) will be releasing its Q4 2025 earnings before the market opens on Thursday, February 26. (View Earnings Report at...

Vericel Corporation $VCEL Shares Acquired by CenterBook Partners LP

CenterBook Partners LP increased its position in shares of Vericel Corporation (NASDAQ:VCEL - Free Report) by 171.1% in the 3rd quarter, according to its most recent disclosure with the Securities...

GSA Capital Partners LLP Buys 40,892 Shares of Vericel Corporation $VCEL

GSA Capital Partners LLP raised its stake in Vericel Corporation (NASDAQ:VCEL - Free Report) by 174.0% during the third quarter, according to its most recent disclosure with the Securities and...

TimesSquare Capital Management LLC Raises Position in Vericel Corporation $VCEL

TimesSquare Capital Management LLC grew its stake in Vericel Corporation (NASDAQ:VCEL - Free Report) by 12.6% during the third quarter, according to its most recent Form 13F filing with the...

New York State Common Retirement Fund Sells 874,932 Shares of Vericel Corporation $VCEL

New York State Common Retirement Fund decreased its stake in shares of Vericel Corporation (NASDAQ:VCEL - Free Report) by 98.3% during the third quarter, according to the company in its most recent...

Thrivent Financial for Lutherans Trims Stock Holdings in Vericel Corporation $VCEL

Thrivent Financial for Lutherans lowered its stake in shares of Vericel Corporation (NASDAQ:VCEL - Free Report) by 36.8% during the third quarter, according to the company in its most recent...

Vericel (NASDAQ:VCEL) Shares Down 5.5% - Should You Sell?

Vericel (NASDAQ:VCEL) Stock Price Down 5.5% - Here's Why...

Brown Capital Management LLC Has $61.40 Million Holdings in Vericel Corporation $VCEL

Brown Capital Management LLC trimmed its holdings in Vericel Corporation (NASDAQ:VCEL - Free Report) by 30.6% in the third quarter, according to the company in its most recent Form 13F filing with...

Federated Hermes Inc. Has $28.15 Million Holdings in Vericel Corporation $VCEL

Federated Hermes Inc. cut its position in shares of Vericel Corporation (NASDAQ:VCEL - Free Report) by 21.9% during the third quarter, according to the company in its most recent disclosure with the...

Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.

Current Price	$38.09
Prev Close	$38.17
Open	$37.88
Dividend Yield	0.00%
50-Day Moving Average	$37.04
Beta	1.21
Avg. Volume	541,892.80
PE Ratio	158.18

52-Week High	$55.41
52-Week Low	$29.24
Market Capitalization	$1.93B
EPS (Annual)	$0.2005
Price to Book	5.98
Revenue Per Employee	$664,493.00

VCEL
Vericel Corp

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VCEL News

VCELVericel Corp